In the News

January 20, 2026

The Healthcare Technology Report - The Top Healthcare Technology CEOs of 2025

January 20, 2026

Medscape - It’s 2026, and We Still Don’t Know Much About Long-Term GLP Use

January 12, 2026

Longevity Technology - MetaVia’s DA-1726 shows early promise in obesity treatment

January 9, 2026

Drug Discovery World - Statistically significant PhI results for GLP-1/glucagon dual agonist

January 8, 2026

The Medicine Maker - A Turning Point in MASH

January 6, 2026

Bio-IT World - Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization

January 5, 2026

Fierce Biotech - MetaVia weighs in with 9% loss as dual agonist enters the obesity ring

December 28, 2025

Today's Clinical Lab - Seven Emerging Trends Shaping Clinical Labs in 2026

November 7, 2025

Investors Business Daily - The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.

November 4, 2025

Pharmaceutical Online - Shaping The Future Of GLP-1 Quality

November 4, 2025

Health Tech World - Breaking into the 50 billion dollar GLP-1 market

August 27, 2025

SCRIP Citeline - A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

August 14, 2025

Longevity Technology - Weight loss drugs: ‘Side effects shouldn’t be the price of progress’

August 6, 2025

Applied Clinical Trials - MetaVia Expands GLP-1 Glucagon Receptor Agonist Obesity Trial Amid Signs of Superior Tolerability

August 5, 2025

Pharmaceutical Executive - MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery

August 4, 2025

First Word Pharma - Metavia taps Syntekabio to explore new avenues for MASH drug with AI

July 29, 2025

Pharmaceutical Commerce - Weighing Cost Savings Against Safety and Regulatory Risks

July 23, 2025

Pharmaceutical Commerce - Can Dual Agonists Deliver Better Outcomes?

July 22, 2025

Pharmaceutical Commerce - Coverage Gaps and Challenges Ahead for Obesity Drugs

July 18, 2025

MedCity News - Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery

July 2, 2025

The Medicine Maker - New Weight-Loss Drug Aims for Results Without Harsh GI Effects

July 1, 2025

Technology Networks Drug Discovery - Beyond the Scale: How Targeted Weight Loss Transforms Metabolic Health and Lowers Healthcare Costs

May 19, 2025

Drug Discovery World - Novel GPR119 agonist shows promise in MASH and diabetes